A new Periodic Transaction Report shows Rep. Julia Letlow (R-La.) sold shares of AbbVie Inc. (ABBV) common stock on January 24, 2025. The transaction was disclosed in a filing with the U.S. House of Representatives and is valued in the $1,001 to $15,000 range, the smallest bracket used on STOCK Act disclosure forms.
The sale was made personally by the member of Congress and was held through a Merrill Lynch Investment Account, identified in the filing as Account #025. No other assets or transactions are listed alongside this entry in the report reviewed for this story.
What stands out most in this filing isn’t the size of the trade, it’s the timing of the disclosure. The transaction occurred on January 24, 2025, but the report was not filed until roughly 199 days later, well past the 45-day window required under the STOCK Act for members of Congress to disclose covered transactions. The filing does not offer an explanation for the gap, and none is speculated on here.
Not the First Late AbbVie Filing From This Office
This isn’t the first time an AbbVie transaction tied to Rep. Letlow’s disclosures has landed outside the required window. Our earlier coverage detailed a separate AbbVie purchase reported 292 days late, meaning the two most recent ABBV-related filings from this office have both cleared the 45-day deadline by wide margins. Whether that reflects a pattern in how trades in this particular stock get reported, or simply overlapping paperwork delays, isn’t something the filings themselves clarify.
Late disclosures like this one are a recurring theme in coverage of congressional stock trading, and they’re part of why tools tracking congress stock act violations and portfolio activity have grown popular among readers trying to follow trading patterns among elected officials. The STOCK Act requires disclosure, not real-time reporting, and enforcement of the 45-day rule has historically been inconsistent across both chambers.
For now, the filing itself is straightforward: a sale of ABBV shares, in a modest dollar range, executed through a Merrill Lynch brokerage account, and reported to the public well after the legal deadline had passed. We classify this signal simply as a congress sale, with the delay noted as a distinct and separate fact from the trade itself.
As with all disclosures covered here, this report is presented as public record. It is not investment guidance, and the timing gap noted above is a matter of filing compliance, not an implication of wrongdoing.